Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference
May 28 2019 - 6:00AM
Athersys, Inc. (NASDAQ: ATHX) announced today its participation in
several sessions at this year’s International Society for Cell and
Gene Therapy (ISCT) conference taking place May 29 – June 2, 2019
in Melbourne, Australia. ISCT 2019 is the largest global
translation-focused cell and gene therapy (CGT) meeting and is
expected to draw delegates from more than 50 countries. Athersys
will play an active role in the meeting, beginning with a
presentation on May 29, 2019 during the Clinical Trial Part 1
Session: MSC Sources, Applications and “Off the Shelf” Products.
Dr. Robert Mays, Vice President of Regenerative Medicine and Head
of Neuroscience Programs at Athersys, will give a presentation
titled “Clinical Development of MultiStem®, an Adult Stem Cell
Therapy, for Treatment of Acute Injuries of the Central Nervous
System”.
On May 30, 2019, Dr. Manal Morsy, Senior Vice President and Head
of Global Regulatory Affairs at Athersys, will share her regulatory
experience and expertise as a panel participant, titled “Regulatory
Impact on Global Commercialization of Cell & Gene
Therapies”.
On May 31, 2019, Dr. Mays, who is the Chairman of the
Neuroscience committee for ISCT, will take the podium again during
a session update for CGT clinical trial and acute central nervous
system injuries. The title of his presentation is
“Translationally Conserved Mechanisms of Benefit Underlying
MultiStem Cell Therapy for Treating Acute Neurological Injury”.
Later the same day, Dr. Anthony Ting, Vice President of
Regenerative Medicine and Head of Cardiopulmonary Programs at
Athersys will chair a Plenary session titled “Understanding the
Challenges to Harmonizing CGT Clinical Trials Across Multiple
Countries”.
About ISCT
The mission of ISCT is to drive translation of all cellular
therapies for the benefit for patients worldwide, with a vision to
improve patients' lives through safe and effective cellular
therapies. Established in 1992, ISCT is a growing global society of
clinicians, regulators, researchers, technologists and industry
partners. ISCT is the global leader focused on pre-clinical and
translational aspects of developing cell-based therapeutics,
thereby advancing scientific research into innovative treatments
for patients. ISCT offers a unique collaborative environment that
addresses three key areas of translation: Academia, Regulatory and
Commercialization. Through strong relationships with global
regulatory agencies, academic institutions and industry partners,
ISCT leads the advancement of research into standard of care.
About Athersys
Athersys is an international biotechnology company engaged in
the development of therapeutic products designed to extend and
enhance the quality of human life. The Company is developing its
MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, cardiovascular, and inflammatory
and immune disease areas, and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. More information is available at
www.athersys.com.
William (B.J.) LehmannPresident and Chief Operating OfficerTel:
(216) 431-9900bjlehmann@athersys.com
Karen HunadyDirector of Corporate Communications &
Investor RelationsTel: (216) 431-9900khunady@athersys.com
David SchullRusso Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024